FY2027 Earnings Estimate for VKTX Issued By William Blair

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Stock analysts at William Blair issued their FY2027 EPS estimates for shares of Viking Therapeutics in a note issued to investors on Wednesday, February 5th. William Blair analyst A. Hsieh expects that the biotechnology company will post earnings of ($2.42) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.41) per share.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same period in the prior year, the firm earned ($0.25) earnings per share.

Other equities research analysts have also issued reports about the stock. Piper Sandler lowered their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a report on Thursday. B. Riley reaffirmed a "buy" rating and set a $96.00 target price (down from $109.00) on shares of Viking Therapeutics in a research report on Friday. Raymond James increased their price target on Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a report on Thursday. HC Wainwright restated a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a report on Thursday. Finally, Maxim Group reduced their target price on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating for the company in a research note on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $96.92.

Viking Therapeutics Price Performance

NASDAQ VKTX traded down $2.39 on Friday, reaching $30.17. The company had a trading volume of 4,633,588 shares, compared to its average volume of 4,020,781. The firm has a 50-day moving average of $40.05 and a 200-day moving average of $53.92. Viking Therapeutics has a 1 year low of $29.82 and a 1 year high of $99.41. The firm has a market capitalization of $3.36 billion, a PE ratio of -30.17 and a beta of 0.90.

Insider Transactions at Viking Therapeutics

In other Viking Therapeutics news, CFO Greg Zante sold 50,309 shares of the business's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $42.75, for a total value of $2,150,709.75. Following the transaction, the chief financial officer now owns 165,259 shares of the company's stock, valued at approximately $7,064,822.25. The trade was a 23.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian Lian sold 194,490 shares of the firm's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $8,314,447.50. Following the completion of the sale, the chief executive officer now owns 2,366,570 shares of the company's stock, valued at approximately $101,170,867.50. This trade represents a 7.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 299,014 shares of company stock worth $12,782,849 over the last three months. 4.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Viking Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. WealthTrust Asset Management LLC raised its holdings in Viking Therapeutics by 6.7% during the 4th quarter. WealthTrust Asset Management LLC now owns 6,923 shares of the biotechnology company's stock worth $279,000 after purchasing an additional 437 shares during the last quarter. Royce & Associates LP increased its stake in shares of Viking Therapeutics by 464.4% in the 4th quarter. Royce & Associates LP now owns 75,261 shares of the biotechnology company's stock valued at $3,029,000 after acquiring an additional 61,927 shares during the last quarter. Monimus Capital Management LP acquired a new stake in shares of Viking Therapeutics in the 4th quarter valued at approximately $845,000. Commonwealth Equity Services LLC boosted its stake in Viking Therapeutics by 27.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 71,193 shares of the biotechnology company's stock worth $2,865,000 after acquiring an additional 15,244 shares during the last quarter. Finally, Vestcor Inc grew its holdings in Viking Therapeutics by 39.3% during the fourth quarter. Vestcor Inc now owns 16,300 shares of the biotechnology company's stock valued at $656,000 after purchasing an additional 4,600 shares during the period. Institutional investors own 76.03% of the company's stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.